Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy

Speight, J.; Hussain, S.; Anandhakrishnan, A.; Danne, T.; Latres, E.; Karpen, S. R.; Mytkolli, L.; Scibilia, R.; Soeholm, U.; Senior, P. A.; Vallis, M.; De Wit, M.; Read, M.; Press, C.; Pokerznik, M. A.; Piemonti, L.; Nutt, D.; Mcleod, H.; Marinac, M.; Lally, J.; Keighron, C.; Jefferson, S.; Del Pozo, C. H.; Heller, S. R.; Greeno, B.; Gibson, K.; Forbes, S.; Ehrmann, D.; Dutta, S.; Cooke, D.; Cleal, B.; Berishvili, E.; Albanese-O'Neill, A.; Ahnstedt, H.; Adams, D.

doi:10.1038/s41591-026-04201-3

Stem-cell-derived islet cells could transform type 1 diabetes by removing the need for injected or infused insulin and improving quality of life. But evaluation of these therapies must center on the voices of people living with type 1 diabetes and examine meaningful outcomes.

Adults with type 1 diabetes define what matters to them in stem-cell derived islet cell therapy / Speight, J., Hussain, S., Anandhakrishnan, A., Danne, T., Latres, E., Karpen, S.R., Mytkolli, L., Scibilia, R., Soeholm, U., Senior, P.A., Vallis, M., De Wit, M., Read, M., Press, C., Pokerznik, M.A., Piemonti, L., Nutt, D., Mcleod, H., Marinac, M., Lally, J., et al.. - In: NATURE MEDICINE. - ISSN 1078-8956. - 32:3(2026), pp. 797-801. [10.1038/s41591-026-04201-3]